March 18, 2024 |
We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.
I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:
Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:
Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
In early 2021, due to COVID-19-related safety concerns and travel and social distancing restrictions, our client needed help to “virtualize” their nationwide, multi-day, multi-business unit internal event with 375 attendees….
A version of this article was previously published on Pharmaphorum.There is not a single industry that has been left untouched by COVID-19. While the effects of the pandemic have been devastating…
Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine…
It’s hard to imagine a time when some people in the life science industry had never attended a web meeting. Yet, that’s the reality we were living in just two…
For many companies, the transition from in-office to remote or flexible work at the beginning of the pandemic may have started off a bit rocky. However, a recent survey from LinkedIn…
Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can…
As I explored in a recent article previously published on Pharmaphorum, the ways that pharmaceutical and scientific communities attend meetings and events completely changed in 2020. Virtual events are rapidly improving, as…
Dr. Dhiren Thakker, Founding President and CEO at Med Aditus, shares his insights into how blockchain and other leading-edge technologies can help revolutionize pharmaceutical manufacturing in sub-Saharan Africa and globally….
What advisors and participants have to say about the Impetus InSite Platform!
New to asynchronous touchpoints? Don’t know where to start? Need help designing an asynchronous event that will engage your stakeholders and give you the insights you’re looking for? In addition…
